ClotProtect Therapeutics Limited
ClotProtect Therapeutics Limited is a UK-based therapeutics spin-out from the University of Leeds, pioneering a first-in-class small molecule anti-fibrinolytic to address acute bleeding. The company is led by a team of world-leading scientific experts, clinical key opinion leaders, and experienced pharma industry professionals. Their mission is to transform the treatment of acute haemorrhage and traumatic bleeding, aiming to save lives with innovative, more effective therapies. ClotProtect is currently in preclinical development, working towards identifying a clinical drug candidate that offers superior efficacy and safety compared to current standards of care.
ClotProtect Therapeutics Limited
Nexus, Discovery Way, Leeds, United Kingdom, LS2 3AA
ClotProtect Therapeutics Limited is currently seeking investment
ClotProtect Therapeutics Limited is seeking a seed investment in the range of 5m-20m
What We Do
A first-in-class small molecule inhibitor of plasmin, designed to prevent clot breakdown with superior potency and clot protection compared to the current standard of care, Tranexamic Acid (TXA). CP-101 offers anticipated superiority in both efficacy and safety, with a unique mode of action that blocks plasmin from all three pathways (tPA, uPA, and kallikrein), potentially reducing mortality, inflammation, and hospital stays in patients at risk of acute bleeding. Currently in preclinical development.
Key People
CEO, Co-Founder, Biology Lead
Co-Founder, Chemistry Lead
CBO & Co-Founder
Chairman
News & Updates
Example placeholder post. No substantive article content provided.